Representative results of the LOH analysis at the p73 (a-c), and PTEN (d) loci. LOH, loss of heterozygosity; i, instability; L, lymphoma; N, normal sample; n, non-digested; d, digested. PCR amplifications were performed in a Perkin Elmer 2400 DNA thermal cycler (Norwalk, CT, USA), and the final products were resolved in 6% denaturing acrylamide 1 × TBE buffered gels. After electrophoresis, the DNA fragments were detected by silver staining. Amplifications corresponding to the StyI polymorphism were digested overnight and analyzed in 2% agarose gels stained with ethidium bromide.
. P73 is a new member of the p53 family that is frequently deleted in neuroblastoma and other human cancers. 5 Interestingly, transcriptional silencing of this gene in lymphoid malignancies due to hypermethylation of its 5Ј CpG island has been recently reported. 6 However, allelic losses were not detected in the cell lines exhibiting lack expression of this gene.
Here, we report an LOH study in 42 paired normal and primary NHLs samples of B and T cell lineage (Table 1) , using polymorphic DNA markers located into/or near PTEN and p73 loci. Lymphomas 
Data from INK4a/ARF and P53 loci derived from previous papers (see Ref. 1) . N, normal: normal and tumor sample are heterozygous and there is no evidence of any difference between the samples; NI, non-informative: both normal and tumor are homozygous and there is no evidence of genetic alterations. LOH, loss of heterozygosity, partial or total elimination of one of the two alleles in the tumor sample; i, microsatellite instability, tumor samples show allelic variant of different size with respect to that of the normal samples; NS, non-studied; M, mutation. WHO Classification: (1) angioimmunoblastic T cell; (2) peripheral T cell (lymphoepithelioid); (3) peripheral T cell (pleomorphic); (4) peripheral T cell (pleomorphic medium cell); (5) mantle cell lymphoma; (6) follicular; (7) diffuse large cell lymphoma (centroblastic); (8) diffuse large cell lymphoma (lymphoblastic); (9) diffuse large cell lymphoma (anaplasic large cell); (10) Burkitt; (11) marginal zone B cell lymphoma (gastric MALT) and (12) unclassifiable B cell NHL.
were classified according to the criteria of the World Health Organization (WHO). PTEN was analyzed using two flanking (D10S5798 and D10S541) and one internal (AFM086WG9) polymorphic short tandem repeats, following the conditions described in Li et al. 2 P73 was analyzed using the microsatellites D1S243 and D1S468, and one internal RL-PCR polymorphism based on the differential digestion of an amplified fragment with the endonuclease StyI. 5 Allelic losses for each microsatellite markers were scored as described previously by Herranz et al. 1 We considered that microsatellite instability occurred when mobility shifts resulting in alleles other than those present in the normal sample were detected in the paired primary tumor.
LOH studies with the mentioned DNA markers allowed us to detect LOH or instabilities in 2/8 (25%) of T-NHLs and 6/34 (17.64%) of B-NHLs. These results, together with previous data we had obtained for the locus INK4a and p53 gene, are indicated in Table 1 . With regard to p73, Schultheis et al 7 have reported heterozygous deletion at D1Z2 region (which presumably contains p73 gene) in 6/74 (8.10%) patients with multiple myeloma. However, neither allelic losses nor rearrangement of p73 were found in any of the studied cell lines from lymphoid malignancies that lack expression of this gene. Interestingly, we detected loss of heterozygosity or microsatellite instability for the internal p73-Sty1 marker in 1/4 informative T cell NHLs (25%), and in 2/17 informative B cell NHLs (11.76%). The number of B-NHLs with p73 alterations increases to 6/17 (32.29%) when we also consider the microsatellites D1S468 and D1S243 (Figure 1a-c) , thus reinforcing the role for this gene in hematological malignancies. On the other hand, it has been proposed that myeloid neoplasias lacking p53 alterations might show a loss of heterozygosity at 1p35-1p36 (where p73 gene is located), 7 but this relationship is not clear in NHLs. Our results showed that only two of the six NHLs with alterations at p73, also have mutated p53. Conversely, only two of the six NHLs with mutated p53 also exhibit p73 alterations.
Deletions and rearrangements of 10q22-25 have been described in a fraction (5-10%) of NHLs. Recently, Butler et al 8 have reported somatic mutations in 2/10 of Burkitt's lymphoma cell lines, and in 2/64 of primary NHL of B cell lineage. However, cytogenetic analyses carried out in a subgroup of NHLs revealed 10q22-25 abnormalities in the absence of mutations or deletions of PTEN. In our work, results obtained with PTEN should be considered with caution since only D10S541 (an external marker) was informative in our samples ( Figure  1d ). We detected one case of genetic instability in a peripheral T cell (L-369) and a diffuse large cell lymphoma (lymphoblastic) (L-272), and two cases of LOH in B-NHLs (L-91, follicular, and L-421, diffuse large cell lymphoma-anaplastic large cell). However, the coexistence of LOH and a translocation t(14; 18) in the centrocytic L-91 tumor (data not shown) is in accordance with a cooperative effect between these two abnormalities during the malignant transformation of NHLs, previously suggested by Siebert et al. 4 In spite of the reduced size of this sample, our results suggest that alterations of the apoptotic signalling pathway involving p73 and PTEN might be considered as an important event in the development of a fraction of NHLs. However, further studies are needed to assess this hypothesis.
